Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089100045> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3089100045 endingPage "S1036" @default.
- W3089100045 startingPage "S1036" @default.
- W3089100045 abstract "ALTER1202 trial,the phase II study has demonstrated that anlotinib significantly prolonged progress-free survival (PFS) in relapsed small cell lung cancer(SCLC) patients as 3rd or further line treatment. Here, we performed a comparative analysis for patients with pleural metastases/pleural effusion in the placebo and anlotinib group. Eligible either limited- or extensive-stage SCLC pts who failed ≥ 2 lines of chemotherapy were randomized 2:1 to receive anlotinib or placebo (12 mg QD from day 1 to 14 of a 21-day cycle) till progression or intolerable toxicity. The primary endpoint was PFS. This subgroup analysis was based on patients with pleural metastases/pleural effusion at baseline. There are 42 patients with pleural metastases/pleural effusion in anlotinib and placebo groups (27 vs. 15). Anlotinib significantly improved PFS (2.83 vs. 0.69 months; HR =0.10; 95% CI, 0.03–0.28; P＜0.0001) compared to placebo and prolonged the overall suirval of 3.75 months without statistical significance (6.51 vs. 2.76 months; HR = 0.52; 95% CI, 0.22–1.23; P =0.1285) compared to placebo. The objective response rate was 3.85% in the anlotinib group and 0% in the placebo group (P =0.442). 16(61.54%) patients in the anlotinib group and no patient in the placebo group had stable disease. The disease control rate was significantly higher in the anlotinib group (65.38%) than in the placebo group (0, P =0.000043). There was no complete response in either group. The most common adverse events in anlotinib group were hypertension (37.04%), fatigue (29.63%) and loss of appetite (29.63%) while in placebo group were γ- glutamyl transferase elevation (20.00%) and loss of appetite (20.00 %). Anlotinib, administrate as 3rd or further line treatment, was well-tolerated and significantly prolonged PFS of relapsed SCLC patients with pleural metastases/pleural effusion." @default.
- W3089100045 created "2020-10-01" @default.
- W3089100045 creator A5004045046 @default.
- W3089100045 creator A5008440809 @default.
- W3089100045 creator A5013800481 @default.
- W3089100045 creator A5026332517 @default.
- W3089100045 creator A5028624269 @default.
- W3089100045 creator A5030035495 @default.
- W3089100045 creator A5047219755 @default.
- W3089100045 creator A5048287456 @default.
- W3089100045 creator A5050913370 @default.
- W3089100045 creator A5057704753 @default.
- W3089100045 creator A5074447759 @default.
- W3089100045 creator A5086270619 @default.
- W3089100045 date "2020-09-01" @default.
- W3089100045 modified "2023-10-17" @default.
- W3089100045 title "1787P Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER1202)" @default.
- W3089100045 doi "https://doi.org/10.1016/j.annonc.2020.08.1548" @default.
- W3089100045 hasPublicationYear "2020" @default.
- W3089100045 type Work @default.
- W3089100045 sameAs 3089100045 @default.
- W3089100045 citedByCount "3" @default.
- W3089100045 countsByYear W30891000452022 @default.
- W3089100045 countsByYear W30891000452023 @default.
- W3089100045 crossrefType "journal-article" @default.
- W3089100045 hasAuthorship W3089100045A5004045046 @default.
- W3089100045 hasAuthorship W3089100045A5008440809 @default.
- W3089100045 hasAuthorship W3089100045A5013800481 @default.
- W3089100045 hasAuthorship W3089100045A5026332517 @default.
- W3089100045 hasAuthorship W3089100045A5028624269 @default.
- W3089100045 hasAuthorship W3089100045A5030035495 @default.
- W3089100045 hasAuthorship W3089100045A5047219755 @default.
- W3089100045 hasAuthorship W3089100045A5048287456 @default.
- W3089100045 hasAuthorship W3089100045A5050913370 @default.
- W3089100045 hasAuthorship W3089100045A5057704753 @default.
- W3089100045 hasAuthorship W3089100045A5074447759 @default.
- W3089100045 hasAuthorship W3089100045A5086270619 @default.
- W3089100045 hasBestOaLocation W30891000451 @default.
- W3089100045 hasConcept C126322002 @default.
- W3089100045 hasConcept C141071460 @default.
- W3089100045 hasConcept C142724271 @default.
- W3089100045 hasConcept C168563851 @default.
- W3089100045 hasConcept C187960798 @default.
- W3089100045 hasConcept C203092338 @default.
- W3089100045 hasConcept C204787440 @default.
- W3089100045 hasConcept C27081682 @default.
- W3089100045 hasConcept C2776232967 @default.
- W3089100045 hasConcept C2776256026 @default.
- W3089100045 hasConcept C2779634585 @default.
- W3089100045 hasConcept C44249647 @default.
- W3089100045 hasConcept C71924100 @default.
- W3089100045 hasConcept C90924648 @default.
- W3089100045 hasConceptScore W3089100045C126322002 @default.
- W3089100045 hasConceptScore W3089100045C141071460 @default.
- W3089100045 hasConceptScore W3089100045C142724271 @default.
- W3089100045 hasConceptScore W3089100045C168563851 @default.
- W3089100045 hasConceptScore W3089100045C187960798 @default.
- W3089100045 hasConceptScore W3089100045C203092338 @default.
- W3089100045 hasConceptScore W3089100045C204787440 @default.
- W3089100045 hasConceptScore W3089100045C27081682 @default.
- W3089100045 hasConceptScore W3089100045C2776232967 @default.
- W3089100045 hasConceptScore W3089100045C2776256026 @default.
- W3089100045 hasConceptScore W3089100045C2779634585 @default.
- W3089100045 hasConceptScore W3089100045C44249647 @default.
- W3089100045 hasConceptScore W3089100045C71924100 @default.
- W3089100045 hasConceptScore W3089100045C90924648 @default.
- W3089100045 hasLocation W30891000451 @default.
- W3089100045 hasOpenAccess W3089100045 @default.
- W3089100045 hasPrimaryLocation W30891000451 @default.
- W3089100045 hasRelatedWork W2137334501 @default.
- W3089100045 hasRelatedWork W2376438601 @default.
- W3089100045 hasRelatedWork W2381522018 @default.
- W3089100045 hasRelatedWork W2401125325 @default.
- W3089100045 hasRelatedWork W2460818230 @default.
- W3089100045 hasRelatedWork W2796769255 @default.
- W3089100045 hasRelatedWork W3084212778 @default.
- W3089100045 hasRelatedWork W4245293991 @default.
- W3089100045 hasRelatedWork W4301428314 @default.
- W3089100045 hasRelatedWork W4382934055 @default.
- W3089100045 hasVolume "31" @default.
- W3089100045 isParatext "false" @default.
- W3089100045 isRetracted "false" @default.
- W3089100045 magId "3089100045" @default.
- W3089100045 workType "article" @default.